Verrica Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Verrica Pharmaceuticals Inc's ROI in the second quarter of 2026?
Verrica Pharmaceuticals Inc recorded a cumulative net loss of $-31 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -158.24%.

Within the Healthcare sector 670 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3955, from total ROI ranking in the first quarter of 2026 at 4697.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	32.06 %	-8.11 %	-43.63 %	-61.53 %	-73.96 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	14	23	31	12	10
Return On Investment (TTM)	-158.24 %	-94.9 %	-109.48 %	-174.07 %	-325.68 %
VRCA's Overall Ranking	# 3955	# 4697	# 4311	# 4499	# 4560
Seq. Investment Change TTM	4.91 %	14.97 %	9.32 %	0.15 %	-27 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-31	-18	-18	-26	-49

VRCA Company Profile >> Back to VRCA Roi Comparisons >> See Annual VRCA Return On Investment

Return On Investment VRCA's Ranking
Within:	No.
Industry	# 301
Sector	# 671
Overall	# 3955

Return On Investment Statistics
High	Average	Low
-23.46 %	-102.01 %	-325.68 %
(Jun 30 2018)		(Jun 30 2025)

News about Verrica Pharmaceuticals Inc Return on Investment ROI

Verrica Pharmaceuticals Advances Clinical Development of YCANTH for Common Warts Following Positive FDA Meeting

January 4, 2024

by
In a recent announcement, Verrica Pharmaceuticals Inc. revealed that it has received the minutes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development of YCANTH for the treatment of common warts. This meeting was held on November 6, 2023, with the aim of discussing the Phase 3 clinical development plan for the medication.
Verrica Pharmaceuticals, a dermatology therapeutics company specializing in the development of medical interventions for skin diseases, expressed its satisfaction with the outcome of the meeting. The company believes that the Type C meeting successfully achieved its primary objective of obtaining advice and agreement from the FDA on the overall design of a pivotal Phase 3 study of YCANTH, which would support an efficacy supplement for the proposed indication of common warts.

Financial Statements
Verrica Pharmaceuticals Inc's II. Quarter Investments	$ 14 Millions	VRCA's Balance sheet
Verrica Pharmaceuticals Inc's II. Quarter Income	$ -13 Millions	Quarterly VRCA's Income Statement
VRCA's Income by Division		See VRCA's Income by Division

VRCA Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	31	25	65	41	34
Y / Y Investment Growth	22.18 %	-61.1 %	56.5 %	21.11 %	-1.76 %
Net Income in Millions	-18	-77	-67	-24	-35
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-58.27 %	-304.83 %	-103.75 %	-59.35 %	-102.96 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VRCA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VRCA's Competitors
Subscribers only: Roi for Verrica Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for VRCA's Customers

Other Ratios
VRCA's Roa	VRCA's Inventory Turnover Ratio	VRCA's Growth Rates	VRCA's Dividend Statistics
	VRCA's Profitability Ratios	VRCA's Asset Turnover Ratio	VRCA's Dividend Growth
VRCA's Roe	VRCA's Valuation Ratios	VRCA's Financial Strength Ratios	VRCA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:34:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.